Result of AGM

RNS Number : 5880Q

Scancell Holdings Plc

07 November 2012

 

7 November 2012

Scancell Holdings Plc

('Scancell')

 Result of AGM

Scancell Holdings Plc, (AIM: SCLP), the developer of therapeutic cancer vaccines, announces that at the Annual General Meeting, held yesterday, all resolutions were duly passed.

About Scancell

Scancell is developing therapeutic vaccines for the treatment of cancer and infectious diseases based on its ImmunoBody® and Moditope™ technology platforms. Scancell's first cancer vaccine SCIB1 is being developed for the treatment of melanoma.

Treating cancer by vaccination allows small non-toxic doses of a vaccine to be administered to a patient, stimulating an immune response. Effective cancer vaccines need to target dendritic cells to stimulate both parts of the cellular immune system; the helper cell system where inflammation is stimulated at the tumour site; and the cytotoxic T-lymphocyte or CTL response where immune system cells are primed to recognise and kill specific cells.

A limitation of many cancer vaccines currently in development is that they cannot specifically target dendritic cells in vivo. Several groups have demonstrated successful vaccination by growing dendritic cells ex vivo, pulsing them with tumour antigens and re-infusing them. However, this procedure is patient specific, time consuming and expensive. Scancell has developed its breakthrough patent protected ImmunoBody® technology to overcome these limitations.

Scancell has also identified and patented a series of modified epitopes that stimulate the production of killer CD4 that destroy tumours without toxicity. The Directors believe that the Moditope™ platform could have a profound effect on the way that cancer vaccines are developed.

The Directors of the issuer accept responsibility for this announcement.

-ENDS-

For Further Information: Scancell Holdings Plc  Dr Richard Goodfellow, Joint CEO  Professor Lindy Durrant, Joint CEO	+ 44 (0) 74 2323 0497
Visible Value LLP: Annie Cheng, CFA	+ 44 (0) 74 2323 0497  [e-mail]
Cenkos Securities:	[phone]
Camilla Hume Stephen Keys

 

END

 

 

RAGBUBDBCUGBGDR